Roche Holding: Results From Tecentriq Study in Bladder Cancer Positive

Date : 09/30/2019 @ 3:20PM
Source : Dow Jones News
Stock : Roche Holding (QX) (RHHBY)
Quote : 42.45  0.03 (0.07%) @ 8:59PM

Roche Holding: Results From Tecentriq Study in Bladder Cancer Positive

Roche Holding (QX) (USOTC:RHHBY)
Historical Stock Chart

6 Months : From Jul 2019 to Jan 2020

Click Here for more Roche Holding (QX) Charts.

By Carlo Martuscelli


Roche Holding AG (ROG.EB) said Monday that a study of its cancer drug Tecentriq had met its objectives, with the drug showing efficacy in patients with previously untreated, advanced bladder cancer.

The German company said that data from the Imvigor130 phase 3 clinical trial showed Tecentriq combined with chemotherapy improved the amount of time before disease progression when compared with chemotherapy alone. Patients in the study had a form of bladder cancer called urothelial carcinoma.

Tecentriq is an immunotherapy--a type of medicine that is designed to help the immune system fight tumor cells.


Write to Carlo Martuscelli at


(END) Dow Jones Newswires

September 30, 2019 11:05 ET (15:05 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest RHHBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.